benzo[d][1,3]dioxole-5-sulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: benzo[d][1,3]dioxole-5-sulfonic acid
• 英文别名: 1,3-Benzodioxole-5-sulfonic acid
• 化学式: C₇H₆O₅S
• 分子量: 202.188
• InChiKey: WOZCSRYOBKSMBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  81.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzo[d][1,3]dioxole-5-sulfonic acid 在 氯化亚砜 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 异丙醇 、 甲苯 为溶剂， 生成 5-{2-[(E)-2-(2-methoxyphenyl)ethenyl]quinazolin-4-ylthio}-2H-1,3-benzodioxole
  参考文献：
  名称：

  Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations

  摘要：

  DOI：

  10.1080/14756366.2023.2201410
• 作为产物：
  描述：

  1-碘-3,4-亚甲基二氧基苯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 、 二氧化硫脲 作用下， 以 二甲基亚砜 为溶剂， 反应 14.0h， 以82%的产率得到benzo[d][1,3]dioxole-5-sulfonic acid
  参考文献：
  名称：

  空气可持续获取卤化物和二氧化硫脲中的磺酸

  摘要：

  探索了一种可持续且温和的一步法，在空气中使用卤化物和二氧化硫代用品的简便组合来合成芳基和烷基磺酸。廉价的工业原料二氧化硫脲被用作一种生态友好，易于处理的二氧化硫替代物，而空气则被用作绿色氧化剂。芳基和烷基磺酸都在过渡金属催化或无过渡金属的条件下获得。机理研究表明，亚硫酸盐作为该转化的中间体。值得注意的是，该方案已被应用于萘普生，异氧平和布洛芬的后期磺化。

  DOI：

  10.1039/d0gc03135f

文献信息

• Protease Inhibitors
  申请人：Stranix Brent Richard

  公开号：US20100184974A1

  公开（公告）日：2010-07-22

  The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R 2 may be, for example, 2-pyridyl-CH 2 —, 3-pyridyl-CH 2 —, 4-pyridyl-CH 2 —, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R 2a —CO)—, R 2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR 5 R 6 , CH 2 OH or CH 2 OR 7 .

  本发明提供了公式I、IA、IB、Ib或II的HIV蛋白酶抑制剂，或其药学上可接受的盐，其中R2可能是，例如，2-吡啶基-CH2—，3-吡啶基- —，4-吡啶基- —，如本文中所述的磺酰基，包括苯磺酰基或噻吩磺酰基，R2a—CO)—，R2a选自由本文中所述的吡哌啶基、2-吡啶基（未取代或取代为H，或1至4个碳原子的烷基）或本文中所述的吡哌啶胺基，其中R3可能是，例如，本文中所述的苯基或二苯甲基基团，Cx可能是，例如，COOH、CONR5R6、 OH或 OR7。
• Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides
  申请人：ELI LILLY AND COMPANY

  公开号：EP0583960A2

  公开（公告）日：1994-02-23

  This invention provides a novel process for the synthesis of bicyclic aromatic sulfonic acids employing reacting a bicyclic aromatic compound with sulfur trioxide-N,N-dimethylformamide complex in the presence of a water miscible, non-reactive solvent. The resulting sulfonic acid may be converted into the corresponding sulfonyl halide by the reaction with a thionyl halide. This invention further provides a novel process for the synthesis of bicyclic aromatic sulfonamides employing the reaction conditions described supra followed by an ammonolysis or amination. The resulting bicyclic aromatic sulfonamides can then be reacted with an appropriately substituted isocyanate to synthesize diaryl sulfonylureas.

  本发明提供了一种新型的合成双环芳香磺酸的方法，其包括在水溶性、非反应性溶剂存在下，将双环芳香化合物与三氧化硫-二甲基甲酰胺复合物反应。所得到的磺酸可以通过与硫代卤化物反应转化为相应的磺酰卤化物。本发明还提供了一种新型的合成双环芳香磺酰胺的方法，其包括在上述反应条件下，经过氨解或胺化反应。所得到的双环芳香磺酰胺可以与适当取代的异氰酸酯反应，合成二芳基磺酰脲。
• Inhibitors of aspartyl protease
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20020198388A1

  公开（公告）日：2002-12-26

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一种新型磺酰胺类物质，其为天冬氨酸蛋白酶抑制剂。在一种实施例中，本发明涉及一种新型的HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适合于抑制HIV-1和HIV-2蛋白酶活性，因此可以作为抗HIV-1和HIV-2病毒的抗病毒剂优势使用。本发明还涉及使用本发明化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。
• Novel Potassium Channel Blockers
  申请人：Mulla Mushtaq

  公开号：US20100087428A1

  公开（公告）日：2010-04-08

  The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; X 1 is selected from a group consisting of CH 2 , C(═O), C(═NH), NC(═O), R 1 is selected from the group consisting of optionally substituted arylalkyl, and optionally substituted heteroarylalkyl R 2 is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl or heteroaryl or NR 24 R 25 R 3 is selected from the group consisting of hydrogen, halogen, hydroxyl, alkoxy, aryloxy, optionally substituted alkyl, optionally substituted amino, optionally substituted amino sulfonyl or nitrile; R 4 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfamoyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroaryl R 5 may be hydrogen, an optionally substituted alkyl, preferably CH 3 or, NR 4 R 5 may form an optionally substituted saturated or partially saturated 4-7 membered ring with the general formula (II). Wherein; X 2 is C(═O), CH 2 , CH(R 6 ) or C(R 6 )(R 6 ), X 3 is CH 2 , CH(R 7 ), C(R 7 )(R 7 ), NH, N(R 8 ), O or S Each R 6 independently represents optionally substituted amino, optionally substituted amino carbonyl, hydroxyl, optionally substituted acyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalky, optionally substituted aryl or optionally substituted heteroaryl; Each R 7 independently represents optionally substituted amino, optionally substituted amino carbonyl, hydroxyl, optionally substituted acyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalky, optionally substituted aryl or optionally substituted hetero aryl R 8 is optionally substituted acyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; R 24 and R 25 are the same or different and each represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl, n=1 or 2 m=1, 2 or 3 With the proviso that when X 1 is C═O and R 5 is H then R 4 is not: Or Or Where R 4 a, R 5 a and R 6 a are each independently H, C 1-6 alkyl, aryl, heteroaryl, cycloalkyl, or aryl-C 1-6 alkyl; R 10 a is H or C 1-6 alkyl; and R 11 a is C 1-6 alkyl or aryl-C 1-6 alkyl and when X 1 is C═O or CH 2 and R 5 is H then R 4 is not: Where q is 0 to 5, R 3 b is H, OH or alkoxy and R 4 b is NH 2 , phenyl or a C 3-10 heterocycle. The compounds are useful as potassium ion channel inhibitors.

  本发明提供了式（I）的化合物或其盐或药学上可接受的衍生物，其中： X1选择自群组，所述群组由CH2，C（═O），C（═NH），NC（═O）组成， R1选择自群组，所述群组由可选取代的芳基烷基和可选取代的杂芳基烷基组成， R2选择自群组，所述群组由可选取代的烷基，可选取代的芳基或杂芳基或NR24R25组成， R3选择自群组，所述群组由氢，卤素，羟基，烷氧基，芳氧基，可选取代的烷基，可选取代的氨基，可选取代的氨基磺酰基或腈组成； R4选择自群组，所述群组由可选取代的烷基，可选取代的环烷基，可选取代的杂环烷基，可选取代的酰基，可选取代的磺酰基，可选取代的磺酰胺基，可选取代的芳基，可选取代的芳基烷基和可选取代的杂芳基组成， R5可以是氢，可选取代的烷基，优选CH3或NR4R5可以形成具有一般式（II）的可选取代的饱和或部分饱和的4-7成员环： 其中，X2为C（═O）， ，CH（R6）或C（R6）（R6）， X3为 ，CH（R7），C（R7）（R7），NH，N（R8），O或S， 每个R6独立地表示可选取代的氨基，可选取代的氨基羰基，羟基，可选取代的酰基，可选取代的烷氧基，可选取代的芳氧基，可选取代的烷基，可选取代的环烷基，可选取代的芳基烷基，可选取代的芳基或可选取代的杂芳基； 每个R7独立地表示可选取代的氨基，可选取代的氨基羰基，羟基，可选取代的酰基，可选取代的烷氧基，可选取代的芳氧基，可选取代的烷基，可选取代的环烷基，可选取代的芳基烷基，可选取代的芳基或可选取代的杂芳基； R8为可选取代的酰基，可选取代的烷基，可选取代的环烷基，可选取代的芳基烷基，可选取代的芳基或可选取代的杂芳基； R24和R25相同或不同，每个表示氢，可选取代的烷基，可选取代的环烷基，可选取代的芳基烷基，可选取代的芳基或可选取代的杂芳基， n为1或2， m为1，2或3， 但是当X1为C═O且R5为H时，则R4不为： 或 其中，R4a，R5a和R6a各自独立地为H，C1-6烷基，芳基，杂芳基，环烷基或芳基-C1-6烷基； R10a为H或C1-6烷基； R11a为C1-6烷基或芳基-C1-6烷基， 当X1为C═O或 且R5为H时，则R4不为： 其中，q为0至5， R3b为H，OH或烷氧基， R4b为NH2，苯基或C3-10杂环。这些化合物可用作钾离子通道抑制剂。
• PROTEASE INHIBITORS
  申请人：TaiMed Biologics, Inc.

  公开号：US20130158261A1

  公开（公告）日：2013-06-20

  The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R 2 may be, for example, 2-pyridyl-CH 2 —, 3-pyridyl-CH 2 —, 4-pyridyl-CH 2 —, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R 2a —CO)—, R 2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR 5 R 6 , CH 2 OH or CH 2 OR 7 .

  本发明提供了式I、IA、IB、Ib或II的HIV蛋白酶抑制剂，或其药学上可接受的盐，其中R2可以是例如2-吡啶基-CH2-、3-吡啶基- -、4-吡啶基- -、如本公式中所述的磺酰基，包括苯磺酰基或噻吩磺酰基，R2a-CO-，其中R2a是从所述的吡哆酰基、2-吡咯啉基（未取代或取代有1至4个碳原子的烷基）或如本文所述的哌啶基氨基中选择的，其中R3可以是例如如本文所述的苯基或二苯甲基基团，Cx可以是例如COOH、CONR5R6、 OH或 OR7。